These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Goodin DS; Frohman EM; Garmany GP; Halper J; Likosky WH; Lublin FD; Silberberg DH; Stuart WH; van den Noort S; Neurology; 2002 Jan; 58(2):169-78. PubMed ID: 11805241 [No Abstract] [Full Text] [Related]
3. Guidance on new therapies in multiple sclerosis patients. Gonsette RE Lancet; 1996 Jul; 348(9020):136. PubMed ID: 8676708 [No Abstract] [Full Text] [Related]
4. What is new in the treatment of multiple sclerosis? Weinstock-Guttman B; Jacobs LD Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827 [TBL] [Abstract][Full Text] [Related]
6. Consensus statement of the Canadian MS CLinics Network on: the use of disease modifying agents in multiple sclerosis. Oger J; Freedman M Can J Neurol Sci; 1999 Nov; 26(4):274-5. PubMed ID: 10610197 [No Abstract] [Full Text] [Related]
7. Confusion over UK beta-interferon "trials". Dean M Lancet; 2001 Nov; 358(9293):1619. PubMed ID: 11716901 [No Abstract] [Full Text] [Related]
8. Disease modifying treatment in multiple sclerosis. Fuller GN; Bone I J Neurol Neurosurg Psychiatry; 2001 Dec; 71 Suppl 2(Suppl 2):ii20-1. PubMed ID: 11701780 [No Abstract] [Full Text] [Related]
10. Treatment of multiple sclerosis and related disorders: what's new in the past 2 years? Noseworthy JH Clin Neuropharmacol; 2003; 26(1):28-37. PubMed ID: 12567162 [No Abstract] [Full Text] [Related]
11. Editorial: the pitfalls of combination therapy. Vermersch P Int MS J; 2006 Nov; 13(3):75-6. PubMed ID: 17101074 [No Abstract] [Full Text] [Related]
12. Multiple sclerosis: expression of CD1a and production of IL-12p70 and IFN-gamma by blood mononuclear cells in patients on combination therapy with IFN-beta and glatiramer acetate compared to monotherapy with IFN-beta. Hussien Y; Sanna A; Söderström M; Link H; Huang YM Mult Scler; 2004 Feb; 10(1):16-25. PubMed ID: 14760948 [TBL] [Abstract][Full Text] [Related]
13. Comparative studies of glatiramer acetate and interferon beta. Goodin D Int MS J; 2008 Jun; 15(2):39-41. PubMed ID: 18782497 [TBL] [Abstract][Full Text] [Related]
14. Concomitant therapy for multiple sclerosis. Stuart WH; Vermersch P Neurology; 2004 Dec; 63(11 Suppl 5):S28-34. PubMed ID: 15596733 [TBL] [Abstract][Full Text] [Related]
15. More immunotherapy for multiple sclerosis. Hughes RA; Sharrack B J Neurol Neurosurg Psychiatry; 1996 Sep; 61(3):239-41. PubMed ID: 8795592 [No Abstract] [Full Text] [Related]